|  |  |  |  |
| --- | --- | --- | --- |
|  | MEDICAL PRODUCT ALERT | **DRAP ALERT NO.** No II/S/07-22-19 |  |
|  |  | |  |
|  | SUBSTANDARD FAASGABLIN CAPSULES  (MANUFACTURED BY M/S FAAS PHARMACEUTICALS (PVT) LTD., KARACHI)  Date: 28th July 2022.  Target Audience:   * Healthcare Professionals- Physicians, Pharmacists, and Nurses. * General Public   Alert Summary:  The sample of Faasgablin capsules was taken by FID for test/ analysis and sent to CDL, Karachi. Federal Government Analyst declared the batch No. 2210C001 of “Faasgablin capsules” as “Substandard”. Details of the product are given as under:   |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | | Product Name | Batch No. | Mfg. date | Exp. date | Manufactured by | Test/Analysis result of CDL | | Faasgablin capsules | 2210C001 | 01-2022 | 01-2024 | M/s FAAS Pharmaceuticals (Pvt) Ltd., Karachi | Average fill weight: **Does not comply.**  Uniformity of Dosage units by Mass variation: **Does not comply.**  Dissolution: **Does not comply.**  Assay: **Does not comply.** |   Action to be taken/ Advice for Healthcare Professionals and general public: -  DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this Substandardbatch.  If anyone is in possession of the above stated product batch, please do not use. If anyone has used this Substandardbatch, or if anyone suffer an adverse reaction/event having used this product batch, it is advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to Drug Regulatory Authority of Pakistan/National Pharmacovigilance Centre.  All medical products must be obtained from licensed, authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt. | |  |